Torrent Pharmaceuticals Ltd on Tuesday reported an 11 per cent rise in consolidated net profit at Rs 498 crore in the fourth ...

Torrent Pharma's US business is set to benefit from new launches and stronger growth momentum, while Germany is likely to see ...

Torrent Pharmaceuticals is entering a new chapter as Aman Mehta, next-gen scion of the Mehta family, prepares to take over as ...

Nifty Pharma stocks, including GSK, Jubilant Pharmova, Eris Life, Gland Pharma and Torrent Pharma, saw gains up to 8% as ...

On the operating front, EBITDA for the quarter was reported at ₹964 Crore. It was 9.20% higher than ₹883 in Q4FY24.

The drugmaker, part of the ₹45,000-crore Torrent Group, also announced a leadership transition. As part of a long-term ...

Torrent Pharmaceuticals reports strong revenue growth in key markets, posting a 15.4% rise in net profit for FY 2024-25.

Torrent Pharmaceuticals reported steady growth in Q4 with an 11% rise in profit and strong margins. The board recommended a ...

With the stock's price at Rs 3222.50, Torrent Pharmaceuticals' performance reflects its position in the pharmaceutical sector.

Indian drugmaker Torrent Pharmaceuticals missed fourth-quarter profit and revenue estimates on Tuesday, hurt by currency depreciation in Brazil, its top overseas market by revenue.

Jefferies recommends Buy on DLF, CMS Info Systems, and Torrent Pharma, citing strong fundamentals and growth prospects. Check ...

The rally is being fuelled by solid quarterly results and a string of optimistic fiscal 2026 outlooks from leading drugmakers ...